FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076787033> ?p ?o ?g. }

• W2076787033 endingPage "1949" @default.
• W2076787033 startingPage "1940" @default.
• W2076787033 abstract "Abstract BACKGROUND The objective of this article was to report the results from a randomized trial that evaluated the efficacy and toxicity of adding tirapazamine (TPZ) to chemoradiotherapy in the treatment of patients with head and neck squamous cell carcinomas (HNSCC). METHODS Sixty‐two patients with lymph node‐positive, resectable, TNM Stage IV HNSCC were randomized to receive either 2 cycles of induction chemotherapy (TPZ, cisplatin, and 5‐fluorouracil [5‐FU]) followed by simultaneous chemoradiotherapy (TPZ, cisplatin, and 5‐FU) or to receive the same regimen without TPZ. Patients who did not achieve a complete response at 50 Grays underwent surgical treatment. Stratification factors for randomization included tumor site, TNM stage, and median tumor oxygen tension. The primary endpoint was complete lymph node response. RESULTS The addition of TPZ resulted in increased hematologic toxicity. There was 1 treatment‐related death from induction chemotherapy. The complete clinical and pathologic response rate in the lymph nodes was 90% and 74% for the standard treatment arm and the TPZ arm, respectively ( P = .08) and 89% and 90% at the primary site in the respective treatment arms ( P = .71). The 5‐year overall survival rate was 59%, the cause‐specific survival rate was 68%, the rate of freedom from recurrence was 69%, and the locoregional control rate was 77% for the entire group. There was no difference with regard to any of the outcome parameters between the 2 treatement arms. The significant long‐term toxicity rate also was found to be similar between the 2 arms. CONCLUSIONS The addition of TPZ increased hematologic toxicity but did not improve outcomes in patients with resectable, Stage IV HNSCC using the protocol administered this small randomized study. The combination of induction and simultaneous chemoradiotherapy resulted in excellent survival in these patients. Cancer 2006. © 2006 American Cancer Society." @default.
• W2076787033 created "2016-06-24" @default.
• W2076787033 creator A5012049620 @default.
• W2076787033 creator A5013860869 @default.
• W2076787033 creator A5015083055 @default.
• W2076787033 creator A5025386674 @default.
• W2076787033 creator A5026071814 @default.
• W2076787033 creator A5026151014 @default.
• W2076787033 creator A5044002664 @default.
• W2076787033 creator A5055209297 @default.
• W2076787033 creator A5056109933 @default.
• W2076787033 creator A5071185138 @default.
• W2076787033 creator A5087316611 @default.
• W2076787033 date "2006-03-10" @default.
• W2076787033 modified "2023-10-18" @default.
• W2076787033 title "Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas" @default.
• W2076787033 cites W1868704956 @default.
• W2076787033 cites W1979393053 @default.
• W2076787033 cites W1997518044 @default.
• W2076787033 cites W1999086587 @default.
• W2076787033 cites W2019196167 @default.
• W2076787033 cites W2019830967 @default.
• W2076787033 cites W2021461364 @default.
• W2076787033 cites W2036789410 @default.
• W2076787033 cites W2043945205 @default.
• W2076787033 cites W2046492464 @default.
• W2076787033 cites W2048544046 @default.
• W2076787033 cites W2048968937 @default.
• W2076787033 cites W2064419187 @default.
• W2076787033 cites W2069900690 @default.
• W2076787033 cites W2074308841 @default.
• W2076787033 cites W2080141853 @default.
• W2076787033 cites W2092941680 @default.
• W2076787033 cites W2093596753 @default.
• W2076787033 cites W2130420198 @default.
• W2076787033 cites W2145953677 @default.
• W2076787033 cites W2157607856 @default.
• W2076787033 cites W2157885764 @default.
• W2076787033 cites W2167229055 @default.
• W2076787033 cites W2170253607 @default.
• W2076787033 cites W2271870719 @default.
• W2076787033 cites W4293241248 @default.
• W2076787033 doi "https://doi.org/10.1002/cncr.21785" @default.
• W2076787033 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16532436" @default.
• W2076787033 hasPublicationYear "2006" @default.
• W2076787033 type Work @default.
• W2076787033 sameAs 2076787033 @default.
• W2076787033 citedByCount "57" @default.
• W2076787033 countsByYear W20767870332012 @default.
• W2076787033 countsByYear W20767870332013 @default.
• W2076787033 countsByYear W20767870332014 @default.
• W2076787033 countsByYear W20767870332015 @default.
• W2076787033 countsByYear W20767870332016 @default.
• W2076787033 countsByYear W20767870332017 @default.
• W2076787033 countsByYear W20767870332018 @default.
• W2076787033 countsByYear W20767870332020 @default.
• W2076787033 countsByYear W20767870332021 @default.
• W2076787033 countsByYear W20767870332022 @default.
• W2076787033 crossrefType "journal-article" @default.
• W2076787033 hasAuthorship W2076787033A5012049620 @default.
• W2076787033 hasAuthorship W2076787033A5013860869 @default.
• W2076787033 hasAuthorship W2076787033A5015083055 @default.
• W2076787033 hasAuthorship W2076787033A5025386674 @default.
• W2076787033 hasAuthorship W2076787033A5026071814 @default.
• W2076787033 hasAuthorship W2076787033A5026151014 @default.
• W2076787033 hasAuthorship W2076787033A5044002664 @default.
• W2076787033 hasAuthorship W2076787033A5055209297 @default.
• W2076787033 hasAuthorship W2076787033A5056109933 @default.
• W2076787033 hasAuthorship W2076787033A5071185138 @default.
• W2076787033 hasAuthorship W2076787033A5087316611 @default.
• W2076787033 hasBestOaLocation W20767870331 @default.
• W2076787033 hasConcept C109316439 @default.
• W2076787033 hasConcept C126322002 @default.
• W2076787033 hasConcept C141071460 @default.
• W2076787033 hasConcept C143998085 @default.
• W2076787033 hasConcept C146357865 @default.
• W2076787033 hasConcept C151730666 @default.
• W2076787033 hasConcept C168563851 @default.
• W2076787033 hasConcept C185592680 @default.
• W2076787033 hasConcept C202751555 @default.
• W2076787033 hasConcept C203092338 @default.
• W2076787033 hasConcept C2776283816 @default.
• W2076787033 hasConcept C2776313096 @default.
• W2076787033 hasConcept C2776611710 @default.
• W2076787033 hasConcept C2776694085 @default.
• W2076787033 hasConcept C2778239845 @default.
• W2076787033 hasConcept C2778424827 @default.
• W2076787033 hasConcept C2780456651 @default.
• W2076787033 hasConcept C2780849966 @default.
• W2076787033 hasConcept C2781413609 @default.
• W2076787033 hasConcept C509974204 @default.
• W2076787033 hasConcept C55493867 @default.
• W2076787033 hasConcept C71924100 @default.
• W2076787033 hasConcept C86803240 @default.
• W2076787033 hasConceptScore W2076787033C109316439 @default.
• W2076787033 hasConceptScore W2076787033C126322002 @default.
• W2076787033 hasConceptScore W2076787033C141071460 @default.
• W2076787033 hasConceptScore W2076787033C143998085 @default.

• next